phase readout
saveNCT06308822: Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
ACTIVE_NOT_RECRUITINGupdated 5d ago
community read0 votes
Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
view source ↗
comments(0)
5-min edit window · permanent after that